Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to Sell Rating

Key Points

• Applied Therapeutics (NASDAQ:APLT) has been upgraded to a "sell" rating by Wall Street Zen in a recent report.
• Royal Bank Of Canada reiterated a "sector perform" rating with a target price of $1.50 for the stock, which currently has an average rating of "Hold" and a consensus target price of $6.10.
• Notably, institutional investors hold 98.31% of Applied Therapeutics' stocks, with significant increases in stakes by several firms recently.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "sell" rating in a research note issued on Saturday.

Separately, Royal Bank Of Canada reiterated a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $6.10.

Applied Therapeutics Price Performance

Shares of APLT opened at $0.48 on Friday. The company has a market capitalization of $67.96 million, a price-to-earnings ratio of -1.12 and a beta of 1.82. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The business's 50-day moving average is $0.39 and its 200-day moving average is $0.47.

Institutional Investors Weigh In On Applied Therapeutics

Several large investors have recently made changes to their positions in APLT. CreativeOne Wealth LLC grew its stake in shares of Applied Therapeutics by 132.2% in the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock valued at $25,000 after buying an additional 28,701 shares in the last quarter. Ground Swell Capital LLC bought a new stake in shares of Applied Therapeutics in the 4th quarter valued at approximately $27,000. Toronto Dominion Bank bought a new stake in shares of Applied Therapeutics in the 4th quarter valued at approximately $27,000. Intech Investment Management LLC grew its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock valued at $45,000 after buying an additional 33,567 shares in the last quarter. Finally, Dark Forest Capital Management LP grew its stake in shares of Applied Therapeutics by 54.5% in the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after buying an additional 18,949 shares in the last quarter. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.